Pregnancy Tests Evaluated During Early Gravidity
By LabMedica International staff writers Posted on 22 Apr 2014 |
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).
The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.
In a hospital setting, failure to detect pregnancy can lead to major consequences such as administration of medications that cause birth defects, fetal radiation exposure, or failure to diagnose ectopic pregnancy, which is the leading cause of first-trimester pregnancy-related maternal death.
Scientists at Washington University School of Medicine (St. Louis, MO, USA) tested a wide range of purified hCG and hCGβcf concentrations, which were mixed and tested on two POC devices. By use of those results, a screening method was defined and nine additional POC devices were evaluated. Two solutions containing 500 pmol/L (171 IU/L) intact hCG without hCGβcf and 500 pmol/L intact hCG with 500,000 pmol/L hCGβcf were used to screen all POC devices.
Varying concentrations of intact hCG and hCGβcf were combined in an hCG-negative urine matrix. Each solution was tested in duplicate by use of the SP hCG Combo Rapid Test (Cardinal Health; Dublin, OH, USA) and the OSOM hCG Combo Test (OSOM; Lexington, MA, USA). This screening method was then used to evaluate the performance of nine additional qualitative hCG POC devices. Visible differences in device performance were evident, resulting in the classification of the devices into three distinct groups: best performance, moderate performance, and poor performance.
The two best-performing devices were the Beckman Coulter Icon 20 (Brea, CA, USA) and the Alere hCG Combo (Waltham, MA, USA). The Icon 20 was the only device to exhibit an increased signal when hCGβcf was added to intact hCG. The Alere device was very modestly affected by the addition of hCGβcf. Two other tests present an unacceptable risk of false-negative results to patients after 5–7 weeks of pregnancy and the accuracy of the remaining seven tests was moderately affected by hCG beta core fragment.
Ann M. Gronowski, PhD, the senior author of the study said, “There are three important take home messages here. One, physicians, nurses, and other healthcare professionals need to be educated that this is a problem. Two, manufacturers need to make the possibility of false negatives clearly visible in their package inserts and work to develop better tests. And three, in centers where quantitative blood hCG testing is available, this should be the preferred pregnancy test. Blood testing is not subject to this effect because hCG beta core fragment is not present in serum.” The study was published in the April 2014 issue of the journal Clinical Chemistry.
Related Links:
Washington University School of Medicine
Cardinal Health
Beckman Coulter
In a hospital setting, failure to detect pregnancy can lead to major consequences such as administration of medications that cause birth defects, fetal radiation exposure, or failure to diagnose ectopic pregnancy, which is the leading cause of first-trimester pregnancy-related maternal death.
Scientists at Washington University School of Medicine (St. Louis, MO, USA) tested a wide range of purified hCG and hCGβcf concentrations, which were mixed and tested on two POC devices. By use of those results, a screening method was defined and nine additional POC devices were evaluated. Two solutions containing 500 pmol/L (171 IU/L) intact hCG without hCGβcf and 500 pmol/L intact hCG with 500,000 pmol/L hCGβcf were used to screen all POC devices.
Varying concentrations of intact hCG and hCGβcf were combined in an hCG-negative urine matrix. Each solution was tested in duplicate by use of the SP hCG Combo Rapid Test (Cardinal Health; Dublin, OH, USA) and the OSOM hCG Combo Test (OSOM; Lexington, MA, USA). This screening method was then used to evaluate the performance of nine additional qualitative hCG POC devices. Visible differences in device performance were evident, resulting in the classification of the devices into three distinct groups: best performance, moderate performance, and poor performance.
The two best-performing devices were the Beckman Coulter Icon 20 (Brea, CA, USA) and the Alere hCG Combo (Waltham, MA, USA). The Icon 20 was the only device to exhibit an increased signal when hCGβcf was added to intact hCG. The Alere device was very modestly affected by the addition of hCGβcf. Two other tests present an unacceptable risk of false-negative results to patients after 5–7 weeks of pregnancy and the accuracy of the remaining seven tests was moderately affected by hCG beta core fragment.
Ann M. Gronowski, PhD, the senior author of the study said, “There are three important take home messages here. One, physicians, nurses, and other healthcare professionals need to be educated that this is a problem. Two, manufacturers need to make the possibility of false negatives clearly visible in their package inserts and work to develop better tests. And three, in centers where quantitative blood hCG testing is available, this should be the preferred pregnancy test. Blood testing is not subject to this effect because hCG beta core fragment is not present in serum.” The study was published in the April 2014 issue of the journal Clinical Chemistry.
Related Links:
Washington University School of Medicine
Cardinal Health
Beckman Coulter
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines